Actively Recruiting
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
Led by Institut de cancérologie Strasbourg Europe · Updated on 2023-09-22
60
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
Sponsors
I
Institut de cancérologie Strasbourg Europe
Lead Sponsor
C
Centre National de la Recherche Scientifique, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.
CONDITIONS
Official Title
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with recurrent squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with metastatic disease
- Tumor directly accessible to clinical examination (tumor of oral cavity and of oropharynx) and/or cervical lymphadenopathy accessible to echography allowing to realise biopsy under local anesthesia
- Indication to treatment by anti-PD1 immunotherapy according to French competent authority recommendations
- Performance status 0, 1 or 2
- At least one measurable lesion on RECIST V1.1 criteria
You will not qualify if you...
- Head and neck squamous cell carcinoma accessible to a local treatment
- Cancer of nasopharynx, sinus or nasal cavity
- Other histology than epidermoid
- Patients with contraindication for anti-PD1 immunotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut de cancérologie Strasbourg Europe
Strasbourg, France, 67033
Actively Recruiting
Research Team
V
Valérie SARTORI
CONTACT
M
Manon VOEGELIN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here